abstract: UNASSIGNED: @entity1 increases the incidence of @entity4 significantly. Various hereditary and acquired factors are known for @entity5 . The hereditary factors are two common genetic autosomal mutations including factor V leidan mutation and @entity3 gene mutation. A descriptive- analytical design was conducted on 60 @entity0 with @entity5 who met the inclusion criteria. Two groups with hereditary and acquired risk factors for @entity5 (group A, B, each 30 @entity0 ) were evaluated. All the @entity0 of two groups were evaluated in terms of emboli associated with hereditary and acquired risk factors. Association of @entity5 risk factors' with @entity2 were studied at the beginning of the study and six months after the treatment then the results of two groups were compared. Among @entity0 , 31 (56.4%) were @entity0 .   The mean age of the @entity0 was 44.4  14 years, ranging between 23-75 years. Significant association was observed between the stability of the blood clot in pulmonary vessel, six months after the treatment with genetic risk factors (P=0.03). However, no significant association was between @entity2 and hereditary and acquired risk factors (P=0.24). Based on the significant association between the hereditary risk factors and @entity6 , by taking special prevention and therapy measurements (e.g. genetic engineering), some pulmonary and mortality complications can be prevented and the @entity0 himself and health care system would benefit from this issue.

title: Association of Chronic @entity2 with Hereditary and Acquired Risk Factors for XXXX .

answer: @entity5


abstract: BACKGROUND: Rapid @entity2 has been recently associated with @entity1 at school age, but its influence in respiratory symptoms during infancy is still unknown. METHODS: Answers from 6541 parents living in six different cities of Brazil to the International Study of Wheezing in @entity0 (EISL) questionnaire were analysed. Data from reported weight and height at birth and at one year were used to calculate BMI. Rapid body mass index (BMI) gain was defined by the difference in BMI superior to 1.0z and excessive by the difference superior to 2.0z. RESULTS: Rapid BMI gain was found in 45.8% @entity0 and excessive in 24.4%. @entity0 showed a significantly higher BMI gain than @entity0 . @entity0 with rapid BMI gain showed a significantly higher prevalence of hospitalisation for wheezing (8.8% vs. 6.4%; aOR: 1.4, 95%CI: 1.1-1.8), severe wheezing (18.1% vs. 15.0%; aOR: 1.3, 95%CI: 1.0-1.5) and medical diagnosis of @entity1 (7.5% vs. 5.7%; aOR: 1.3, 95%CI: 1.0-1.7). @entity0 with @entity2 also had a significantly higher prevalence of hospitalisation for wheezing (9.8% vs. 6.7%; aOR: 1.5, 95%CI: 1.1-2.0) and severe wheezing (18.9% vs. 15.5%; aOR: 1.3, 95%CI: 1.0-1.6). No significant association was found among @entity0 . CONCLUSIONS: The majority of the evaluated @entity0 showed BMI gain above expected in the first year of life. Although more commonly found in @entity0 , rapid and @entity2 in the first year of life was significantly related to more severe patterns of wheezing in infancy among @entity0 .

title: Gender differences in the relationship between body mass index (BMI) changes and the prevalence and severity of wheezing and XXXX in the first year of life.

answer: @entity1


abstract: UNASSIGNED: @entity0 is still one of the leading causes of @entity2 worldwide, and finding new treatments remains a major challenge. Previous studies showed that modified forms of pectin, a complex polysaccharide present in the primary plant cell wall, possess anticancer properties. Nevertheless, the mechanism of action of modified pectin and the pathways involved are unclear. Here, we show that citrus pectin modified by heat treatment induced cell @entity2 in HepG2 and A549 cells. The induced cell @entity2 differs from classical apoptosis because no DNA cleavage was observed. In addition, Z-VAD-fmk, a pan-caspase inhibitor, did not influence the observed cell @entity2 in HepG2 cells but appeared to be partly protective in A549 cells, indicating that heat-modified citrus pectin might induce caspase-independent cell @entity2 . An increase in the abundance of the phosphatidylethanolamine-conjugated Light Chain 3 (LC3) protein and a decrease in @entity3 protein abundance were observed in both cell types when incubated in the presence of heat-modified citrus pectin. These results indicate the activation of autophagy. To our knowledge, this is the first time that autophagy has been revealed in cells incubated in the presence of a modified form of pectin. This autophagy activation appears to be protective, at least for A549 cells, because its inhibition with 3-methyladenine increased the observed modified pectin-induced @entity1 . This study confirms the potential of modified pectin to improve chemotherapeutic @entity0 treatments.

title: Heat-Modified Citrus Pectin Induces Apoptosis-Like Cell Death and Autophagy in HepG2 and A549 XXXX Cells.

answer: @entity0


abstract: OBJECTIVES: Presentation of two cases of late postpartum @entity7 that took place at our hospital, one month apart. Eclampsia is defined as generalized @entity4 , in the setting of @entity6 , without other neurologic conditions. With an incidence of 1:2.000 deliveries in developed countries, it occurs in 2% of @entity0 with severe @entity6 and in 0.5% of those with non-severe @entity6 . Although it may occur from gestation to puerperium, it is estimated that only 5-17% of cases take place after 48h postpartum. @entity7 is a clinical diagnosis, most cases present with @entity8 ( @entity8 ) findings on MRI. METHODS: Review of literature and consultation of clinical files. RESULTS: CASE 1 - A 28-year-old female, G2P0, underwent cesarean delivery, at 38 weeks' gestation, in the setting of @entity6 and abnormal nonstress test. On day 6 postpartum, she experienced @entity1 , after which she had three generalized @entity4 . On admission, she was postictal and @entity2 (170/120mmHg), @entity5 4+, normal CT scan and EEG. MRI revealed lesions compatible with PRLS. She was admitted to the ICU and treated with magnesium sulfate, valproate and antihypertensive medication, with no further @entity4 and gradual normalization of blood pressure. CASE 2 - A 31-year-old female, G5P3, with gestational @entity2 , underwent vaginal delivery at 40 weeks' gestation. Since day 2 postpartum she complained of a mild @entity1 . On day 4 she developed @entity3 followed by generalized tonic-clonic @entity4 . At admission to the ICU, BP was 168/110 mmHg. CT and EEG were normal. MRI revealed @entity8 . She underwent therapy with magnesium sulfate, valproate and antihypertensive therapy, with no additional @entity4 and stabilization of blood pressure. CONCLUSIONS: Prompt exclusion of other causes of @entity4 , especially in late presentations, combined with early diagnosis and treatment, are central to avoid morbidity and mortality associated with @entity7 . DISCLOSURES: S. Nascimento: None. R. Gomes: None. T. Matos: None. I. Santos: None. F. Matos: None.

title: [237-POS]: XXXX - A late presentation to keep in mind.

answer: @entity7


abstract: OBJECTIVES: The @entity1 epidemic is of increasing obstetrical concern as these @entity0 are more likely to be @entity2 prior to pregnancy and experience adverse outcomes. The purpose of this study was to examine the perinatal outcomes of conventionally managed @entity1 gravidas with preexisting @entity2 to management guided by hemodynamics obtained from impedance cardiography. METHODS: The Cabell-Huntington Hospital maternal and neonatal charts of all @entity0 hemodynamically evaluated using impedance cardiography weighing 300lbs (136kg) or more (58 study @entity0 ) were reviewed; controls were the most recently delivered 90 @entity0 of similar weight with (n=17) and without (n=73) preexisting @entity2 . Differences demographic, pregnancy and delivery data were assessed by one-way ANOVA for continuous variables and Chi-square analysis for categorical data. RESULTS: There was no difference in age, weight, or BMI or route of delivery. Although delivering at term, the treated @entity0 delivered 12 days earlier. There was no difference in the mean birth weight percentile and rates of @entity4 and @entity5 were similar. Conventionally treated @entity2 @entity1 gravidas spent more days in the hospital as did their @entity0 , possibly because the incidence of severe @entity3 was higher (23% vs 6%) than in those whose antihypertensive therapy was hemodynamically directed. CONCLUSIONS: Obesity is a known risk factor for @entity2 disorders of pregnancy; in @entity1 @entity0 with preexisting @entity2 the risk is markedly higher. In @entity1 @entity0 with preexisting @entity2 , hemodynamically-guided treatment results in fewer cases of severe @entity3 and fewer maternal and neonatal hospital days. D.G. Chaffin: Commercial Interest: MIST, LLC. J. Granger: None.

title: [250-POS]: Pregnancy outcomes of @entity1 XXXX gravidas.

answer: @entity2


abstract: OBJECTIVES: The @entity1 epidemic is of increasing obstetrical concern as these @entity0 are more likely to be @entity2 prior to pregnancy and experience adverse outcomes. The purpose of this study was to examine the perinatal outcomes of conventionally managed @entity1 gravidas with preexisting @entity2 to management guided by hemodynamics obtained from impedance cardiography. METHODS: The Cabell-Huntington Hospital maternal and neonatal charts of all @entity0 hemodynamically evaluated using impedance cardiography weighing 300lbs (136kg) or more (58 study @entity0 ) were reviewed; controls were the most recently delivered 90 @entity0 of similar weight with (n=17) and without (n=73) preexisting @entity2 . Differences demographic, pregnancy and delivery data were assessed by one-way ANOVA for continuous variables and Chi-square analysis for categorical data. RESULTS: There was no difference in age, weight, or BMI or route of delivery. Although delivering at term, the treated @entity0 delivered 12 days earlier. There was no difference in the mean birth weight percentile and rates of @entity4 and @entity5 were similar. Conventionally treated @entity2 @entity1 gravidas spent more days in the hospital as did their @entity0 , possibly because the incidence of severe @entity3 was higher (23% vs 6%) than in those whose antihypertensive therapy was hemodynamically directed. CONCLUSIONS: Obesity is a known risk factor for @entity2 disorders of pregnancy; in @entity1 @entity0 with preexisting @entity2 the risk is markedly higher. In @entity1 @entity0 with preexisting @entity2 , hemodynamically-guided treatment results in fewer cases of severe @entity3 and fewer maternal and neonatal hospital days. D.G. Chaffin: Commercial Interest: MIST, LLC. J. Granger: None.

title: [250-POS]: Pregnancy outcomes of XXXX @entity2 gravidas.

answer: @entity1


abstract: OBJECTIVES: To compare the relative risk of @entity2 and frequency of prenatal visits. METHODS: We evaluated the risk of gestational @entity1 with the number of prenatal visits in 4,247,694 delivered @entity0 included in the CDC 2008 Vital Stats dataset. The incidence of @entity2 among subgroups of @entity0 defined by their number of prenatal visits was calculated. Relative risks were determined for each subgroup by comparing the incidence of @entity2 in each subgroup compared to those @entity0 with 13-14 visits (reference group). These groups were (1) no visits, (2) 1-2 visits, (3) 3-4 visits, (4) 5-6 visits, (5) 7-8 visits, (6) 9-10 visits, (7) 11-12 visits, (8) 13-14 visits {reference group}, (9) 15-16 visits, (10) 17-18 visits, (11) 19 or more visits. RESULTS: The relative risk of @entity2 increased as the number of prenatal visits decreased, with the highest risk among those @entity0 who had no prenatal visits (RR=2.16, 95% CI=1.90-2.45). The relative risk of @entity2 also increased as the number of prenatal visits increased above 13-14 visits. The highest risk was for those @entity0 with 19 or more visits (RR=2.34, 95%, CI=2.13-2.58). CONCLUSIONS: Fewer prenatal visits may be associated with a higher risk of @entity2 . This may be due to iatrogenic @entity3 or poor @entity0 compliance. @entity2 may also be associated with an increased number of prenatal visits. This may be due to close monitoring of a high risk @entity0 . DISCLOSURES: E.T. Greeley: None. K.L. Terry: None. J.V. Spencer: None.

title: [251-POS]: Risk of XXXX compared to number of prenatal visits.

answer: @entity2


abstract: UNASSIGNED: Blood pressure variability ( @entity5 ) has been associated with cardiovascular events; however, the prognostic significance of short-term @entity5 remains uncertain. As uncertainty also remains as to which measure of variability most accurately describes short-term @entity5 , this study explores different indices and investigates their relationship with subclinical @entity2 ( @entity2 ). We used data from the Mitchelstown Study, a cross-sectional study of Irish adults aged 47-73 years (n=2047). A subsample (1207) underwent 24-h ambulatory BP monitoring (ABPM). As measures of short-term @entity5 , we estimated the s.d., weighted s.d. (wSD), coefficient of variation (CV) and average real variability (ARV). @entity2 was documented by microalbuminuria and electrocardiogram (ECG) @entity4 ( @entity4 ). There was no association found between any measure of @entity5 and @entity4 in both unadjusted and fully adjusted logistic regression models. Similar analysis found that ARV (24   h, day and night), s.d. (day and night) and wSD were all univariately associated with microalbuminuria and remained associated after adjustment for age, gender, smoking, body mass index (BMI), @entity1 and antihypertensive treatment. However, when the models were further adjusted for the mean BP the association did not persist for all indices. Our findings illustrate choosing the appropriate summary measure, which accurately captures that short-term @entity5 is difficult. Despite discrepancies in values between the different measures, there was no association between any indexes of variability with @entity2 measures after adjustment for the mean BP.Journal of @entity0 @entity3 advance online publication, 19 March 2015; doi:10.1038/jhh.2015.18.

title: Short-term blood pressure variability over 24   h and XXXX in middle-aged @entity0 and @entity0 .

answer: @entity2


abstract: UNASSIGNED: Blood pressure variability ( @entity5 ) has been associated with cardiovascular events; however, the prognostic significance of short-term @entity5 remains uncertain. As uncertainty also remains as to which measure of variability most accurately describes short-term @entity5 , this study explores different indices and investigates their relationship with subclinical @entity2 ( @entity2 ). We used data from the Mitchelstown Study, a cross-sectional study of Irish adults aged 47-73 years (n=2047). A subsample (1207) underwent 24-h ambulatory BP monitoring (ABPM). As measures of short-term @entity5 , we estimated the s.d., weighted s.d. (wSD), coefficient of variation (CV) and average real variability (ARV). @entity2 was documented by microalbuminuria and electrocardiogram (ECG) @entity4 ( @entity4 ). There was no association found between any measure of @entity5 and @entity4 in both unadjusted and fully adjusted logistic regression models. Similar analysis found that ARV (24   h, day and night), s.d. (day and night) and wSD were all univariately associated with microalbuminuria and remained associated after adjustment for age, gender, smoking, body mass index (BMI), @entity1 and antihypertensive treatment. However, when the models were further adjusted for the mean BP the association did not persist for all indices. Our findings illustrate choosing the appropriate summary measure, which accurately captures that short-term @entity5 is difficult. Despite discrepancies in values between the different measures, there was no association between any indexes of variability with @entity2 measures after adjustment for the mean BP.Journal of @entity0 @entity3 advance online publication, 19 March 2015; doi:10.1038/jhh.2015.18.

title: Short-term blood pressure variability over 24   h and @entity2 in middle-aged XXXX and @entity0 .

answer: @entity0


abstract: UNASSIGNED: Blood pressure variability ( @entity5 ) has been associated with cardiovascular events; however, the prognostic significance of short-term @entity5 remains uncertain. As uncertainty also remains as to which measure of variability most accurately describes short-term @entity5 , this study explores different indices and investigates their relationship with subclinical @entity2 ( @entity2 ). We used data from the Mitchelstown Study, a cross-sectional study of Irish adults aged 47-73 years (n=2047). A subsample (1207) underwent 24-h ambulatory BP monitoring (ABPM). As measures of short-term @entity5 , we estimated the s.d., weighted s.d. (wSD), coefficient of variation (CV) and average real variability (ARV). @entity2 was documented by microalbuminuria and electrocardiogram (ECG) @entity4 ( @entity4 ). There was no association found between any measure of @entity5 and @entity4 in both unadjusted and fully adjusted logistic regression models. Similar analysis found that ARV (24   h, day and night), s.d. (day and night) and wSD were all univariately associated with microalbuminuria and remained associated after adjustment for age, gender, smoking, body mass index (BMI), @entity1 and antihypertensive treatment. However, when the models were further adjusted for the mean BP the association did not persist for all indices. Our findings illustrate choosing the appropriate summary measure, which accurately captures that short-term @entity5 is difficult. Despite discrepancies in values between the different measures, there was no association between any indexes of variability with @entity2 measures after adjustment for the mean BP.Journal of @entity0 @entity3 advance online publication, 19 March 2015; doi:10.1038/jhh.2015.18.

title: Short-term blood pressure variability over 24   h and @entity2 in middle-aged @entity0 and XXXX .

answer: @entity0


abstract: INTRODUCTION: @entity2 @entity0 are at high risk of developing pressure ulcers resulting in serious untoward @entity0 and health care system outcomes. Pressure @entity1 prevention is therefore an important @entity0 safety priority and establishing a structured approach to pressure @entity1 risk assessment to identify @entity0 at risk is a critical first step. METHODS: The literature was searched using three electronic databases from 2000 to 2011 to identify papers reporting on pressure @entity1 risk factors and assessment in adult critical care. The review and appraisal of papers were conducted by two critical care nurses. Papers underwent detailed review if they met inclusion criteria where they identified pressure @entity1 assessment scores, scales or risk factors and related to adult critical care @entity0 FINDINGS: Seven papers were reviewed. No single assessment tool was sufficiently validated for @entity2 @entity0 and seven key critical care risk factors were identified. These risk factors were: mechanical ventilation, impaired circulation, dialysis, long surgery, low protein and too unstable to turn. TOOL DEVELOPMENT: The tool Critical Care Pressure Ulcer Assessment Tool made Easy (CALCULATE) was developed utilizing the risk factors from the literature and expert critical care nursing consensus decision-making. DISCUSSION: In the absence of current consensus, valid assessment scales and limited evidence for the most appropriate pressure @entity1 assessment for @entity2 @entity0 , this assessment tool offers an easy, appropriate alternative for @entity2 @entity0 than existing tools primarily validated for acute care wards. CONCLUSIONS: 'CALCULATE' offers an important contribution towards the advancement and development of critical care pressure @entity1 risk assessment. Future research is needed to further enhance and inform pressure @entity1 risk assessment of the @entity2 @entity0 . IMPLICATIONS FOR PRACTICE: The identification of critical care risk factors may be an indicative method of assessing pressure @entity1 risk in the @entity2 @entity0 .

title: Part 1: Pressure XXXX assessment  -  the development of Critical Care Pressure Ulcer Assessment Tool made Easy (CALCULATE).

answer: @entity1


abstract: The authors had 75 @entity0 with @entity2 under observation. After the 15th day of the disease various @entity1 and conductivity were revealed in 85% of @entity0 during cardiomonitor surveillance. The most frequent occurrences were @entity6 (72.5%), sinus @entity5 (40%) and @entity11 (37.5%). @entity8 was noted in 4 (5.3%) @entity0 two of whom were resuscitated. In 50 @entity0 with @entity2 of more than one month duration @entity1 during physical load were studied (dosed walking under telectrocardiographic control and/or on a treadmill). During dosed waling 28% of @entity0 developed @entity4 or it was intensified (sinus @entity3 was not taken into account). During a load on a treadmill such changes were encountered in 30% of @entity0 . A favourable effect of treatment with @entity9 was produced in most @entity0 with @entity6 some of whom were resistant to lidocain treatment. A good effect was produced in some @entity0 by means of the pulsnorma or rythmodan. Beta-adrenergic blocking agents as well as cordaron and @entity7 were effective in @entity10 . Hyperbaric oxygenation was used in 14 @entity0 with disorders of rhythm. Disappearance of @entity4 or considerable improvement was registered in 11 @entity0 after treatment consisting of 10-12 procedures.

title: [Late XXXX in @entity2 ].

answer: @entity4


abstract: The authors had 75 @entity0 with @entity2 under observation. After the 15th day of the disease various @entity1 and conductivity were revealed in 85% of @entity0 during cardiomonitor surveillance. The most frequent occurrences were @entity6 (72.5%), sinus @entity5 (40%) and @entity11 (37.5%). @entity8 was noted in 4 (5.3%) @entity0 two of whom were resuscitated. In 50 @entity0 with @entity2 of more than one month duration @entity1 during physical load were studied (dosed walking under telectrocardiographic control and/or on a treadmill). During dosed waling 28% of @entity0 developed @entity4 or it was intensified (sinus @entity3 was not taken into account). During a load on a treadmill such changes were encountered in 30% of @entity0 . A favourable effect of treatment with @entity9 was produced in most @entity0 with @entity6 some of whom were resistant to lidocain treatment. A good effect was produced in some @entity0 by means of the pulsnorma or rythmodan. Beta-adrenergic blocking agents as well as cordaron and @entity7 were effective in @entity10 . Hyperbaric oxygenation was used in 14 @entity0 with disorders of rhythm. Disappearance of @entity4 or considerable improvement was registered in 11 @entity0 after treatment consisting of 10-12 procedures.

title: [Late @entity4 in XXXX ].

answer: @entity2


abstract: Among the mechanisms that control chromosome segregation in bacteria are highly-conserved partitioning systems comprising three components: @entity3 protein (a deviant Walker-type ATPase), @entity4 protein (a DNA-binding element) and multiple cis-acting palindromic centromere-like sequences, designated parS. Ten putative parS sites have been identified in the @entity2 genome, four localized in close proximity of oriC and six, diverged by more than one @entity1 from a perfect palindromic sequence, dispersed along the chromosome. Here, we constructed and analyzed @entity0 mutants deprived of each single parS sequence and their different combinations. The analysis included evaluation of a set of phenotypic features, chromosome segregation, and @entity4 localization in the cells. It was found that @entity4 binds specifically to all ten parS sites, although with different affinities. The @entity0 parS mutant with all ten parS sites modified (parSnull) is viable however it demonstrates the phenotype characteristic for parAnull or parBnull mutants: slightly slower growth rate, high frequency of anucleate cells, and defects in motility. The genomic position and sequence of parS determine its role in @entity0 biology. It transpired that any one of the four parS sites proximal to oriC (parS1 to parS4), which are bound by @entity4 with the highest affinity, is necessary and sufficient for the parABS role in chromosome partitioning. When all these four sites are mutated simultaneously, the strain shows the parSnull phenotype, which indicates that none of the remaining six parS sites can substitute for these four oriC-proximal sites in this function. A single ectopic parS2 (inserted opposite oriC in the parSnull mutant) facilitates @entity4 organization into regularly spaced condensed foci and reverses some of the mutant phenotypes but is not sufficient for accurate chromosome segregation.

title: A single parS sequence from the cluster of four sites closest to oriC is necessary and sufficient for proper chromosome segregation in XXXX .

answer: @entity0


abstract: UNASSIGNED: OBJECT Proper screening, management, and follow-up of Grade 1 and 2 blunt @entity8 (BCIs) remains controversial. These low-grade BCIs were analyzed to define their natural history and establish a rational management plan based on lesion progression and @entity5 . METHODS A retrospective review of a prospectively maintained database of all blunt traumatic carotid and vertebral @entity7 treated between August 2003 and April 2013 was performed and Grade 1 and 2 BCIs were identified. Grade 1 injuries are defined as a vessel lumen stenosis of less than 25%, and Grade 2 injuries are defined as a stenosis of the vessel lumen between 25% and 50%. Demographic information, radiographic imaging, number of imaging sessions performed per individual, length of radiographic follow-up, radiographic outcome at end of follow-up, treatment(s) provided, and documentation of @entity5 or transient @entity1 attack were recorded. RESULTS One hundred seventeen Grade 1 and 2 BCIs in 100 @entity0 were identified and available for follow-up. The mean follow-up duration was 60 days. Final imaging of Grade 1 and 2 BCIs demonstrated that 64% of cases had resolved, 13% of cases were radiographically stable, and 9% were improved, whereas 14% radiographically worsened. Of the treatments received, 54% of cases were treated with @entity3 ( @entity6 ), 31% received no treatment, and 15% received various medications and treatments, including endovascular stenting. There was 1 @entity5 that was thought to be related to bilateral Grade 2 BCI, which developed soon after hospital admission. CONCLUSIONS The majority of Grade 1 and 2 BCIs remained stable or improved at final follow-up. Despite a 14% rate of radiographic worsening in the Grade 1 and 2 BCIs cohort, there were no adverse clinical outcomes associated with these radiographic changes. The @entity2 rate was 1% in this low-grade BCIs cohort, which may be an overestimate. The use of @entity6 or other antiplatelet or anticoagulant medications in these low-grade BCIs did not appear to correlate with @entity4 stability, nor with a decreased rate of @entity5 . Although these data suggest that these Grade 1 and 2 BCIs may require less intensive radiographic follow-up, future prospective studies are needed to make conclusive changes related to treatment and management.

title: Clinical and radiographic outcomes following traumatic Grade 1 and 2 XXXX : a 10-year retrospective analysis from a Level I @entity4 center. The Parkland Carotid and @entity7 .

answer: @entity8


abstract: UNASSIGNED: OBJECT Proper screening, management, and follow-up of Grade 1 and 2 blunt @entity8 (BCIs) remains controversial. These low-grade BCIs were analyzed to define their natural history and establish a rational management plan based on lesion progression and @entity5 . METHODS A retrospective review of a prospectively maintained database of all blunt traumatic carotid and vertebral @entity7 treated between August 2003 and April 2013 was performed and Grade 1 and 2 BCIs were identified. Grade 1 injuries are defined as a vessel lumen stenosis of less than 25%, and Grade 2 injuries are defined as a stenosis of the vessel lumen between 25% and 50%. Demographic information, radiographic imaging, number of imaging sessions performed per individual, length of radiographic follow-up, radiographic outcome at end of follow-up, treatment(s) provided, and documentation of @entity5 or transient @entity1 attack were recorded. RESULTS One hundred seventeen Grade 1 and 2 BCIs in 100 @entity0 were identified and available for follow-up. The mean follow-up duration was 60 days. Final imaging of Grade 1 and 2 BCIs demonstrated that 64% of cases had resolved, 13% of cases were radiographically stable, and 9% were improved, whereas 14% radiographically worsened. Of the treatments received, 54% of cases were treated with @entity3 ( @entity6 ), 31% received no treatment, and 15% received various medications and treatments, including endovascular stenting. There was 1 @entity5 that was thought to be related to bilateral Grade 2 BCI, which developed soon after hospital admission. CONCLUSIONS The majority of Grade 1 and 2 BCIs remained stable or improved at final follow-up. Despite a 14% rate of radiographic worsening in the Grade 1 and 2 BCIs cohort, there were no adverse clinical outcomes associated with these radiographic changes. The @entity2 rate was 1% in this low-grade BCIs cohort, which may be an overestimate. The use of @entity6 or other antiplatelet or anticoagulant medications in these low-grade BCIs did not appear to correlate with @entity4 stability, nor with a decreased rate of @entity5 . Although these data suggest that these Grade 1 and 2 BCIs may require less intensive radiographic follow-up, future prospective studies are needed to make conclusive changes related to treatment and management.

title: Clinical and radiographic outcomes following traumatic Grade 1 and 2 @entity8 : a 10-year retrospective analysis from a Level I XXXX center. The Parkland Carotid and @entity7 .

answer: @entity4


abstract: UNASSIGNED: OBJECT Proper screening, management, and follow-up of Grade 1 and 2 blunt @entity8 (BCIs) remains controversial. These low-grade BCIs were analyzed to define their natural history and establish a rational management plan based on lesion progression and @entity5 . METHODS A retrospective review of a prospectively maintained database of all blunt traumatic carotid and vertebral @entity7 treated between August 2003 and April 2013 was performed and Grade 1 and 2 BCIs were identified. Grade 1 injuries are defined as a vessel lumen stenosis of less than 25%, and Grade 2 injuries are defined as a stenosis of the vessel lumen between 25% and 50%. Demographic information, radiographic imaging, number of imaging sessions performed per individual, length of radiographic follow-up, radiographic outcome at end of follow-up, treatment(s) provided, and documentation of @entity5 or transient @entity1 attack were recorded. RESULTS One hundred seventeen Grade 1 and 2 BCIs in 100 @entity0 were identified and available for follow-up. The mean follow-up duration was 60 days. Final imaging of Grade 1 and 2 BCIs demonstrated that 64% of cases had resolved, 13% of cases were radiographically stable, and 9% were improved, whereas 14% radiographically worsened. Of the treatments received, 54% of cases were treated with @entity3 ( @entity6 ), 31% received no treatment, and 15% received various medications and treatments, including endovascular stenting. There was 1 @entity5 that was thought to be related to bilateral Grade 2 BCI, which developed soon after hospital admission. CONCLUSIONS The majority of Grade 1 and 2 BCIs remained stable or improved at final follow-up. Despite a 14% rate of radiographic worsening in the Grade 1 and 2 BCIs cohort, there were no adverse clinical outcomes associated with these radiographic changes. The @entity2 rate was 1% in this low-grade BCIs cohort, which may be an overestimate. The use of @entity6 or other antiplatelet or anticoagulant medications in these low-grade BCIs did not appear to correlate with @entity4 stability, nor with a decreased rate of @entity5 . Although these data suggest that these Grade 1 and 2 BCIs may require less intensive radiographic follow-up, future prospective studies are needed to make conclusive changes related to treatment and management.

title: Clinical and radiographic outcomes following traumatic Grade 1 and 2 @entity8 : a 10-year retrospective analysis from a Level I @entity4 center. The Parkland Carotid and XXXX .

answer: @entity7


abstract: OBJECTIVES: To measure the incidence of @entity4 ( @entity4 ), defined as first-ever @entity3 ( @entity3 ) or @entity5 ( @entity5 ); evaluate recent temporal trends; and determine whether survival after @entity4 has changed over time and differs by type. @entity0 AND METHODS: This was a population surveillance study conducted in Olmsted County, Minnesota (population: 144,248). All @entity0 hospitalized with incident @entity4 between January 1, 2005, and December 31, 2010, were identified using International Classification of Diseases, Ninth Revision codes, natural language processing of the medical records, and biomarkers. @entity3 was validated by epidemiologic criteria and @entity5 by the Braunwald classification. @entity0 were followed through June 30, 2013, for @entity1 . RESULTS: Of 1244 incident @entity4 cases, 35% (n=438) were @entity5 and 65% (n=806) were @entity3 . The standardized rates (per 100,000) of @entity4 were 284 (95% CI, 248-319) in 2005 and 184 (95% CI, 157-210) in 2010 (2010 vs 2005: rate ratio, 0.62; 95% CI, 0.53-0.73), indicating a 38% decline (similar for @entity3 and @entity5 ). The 30-day case fatality rates did not differ by year of diagnosis but were worse for @entity3 (8.9%; 95% CI, 6.9%-10.9%) compared with @entity5 (1.9%; 95% CI, 0.6%-3.1%). Among 30-day survivors, the risk of @entity1 did not differ by @entity4 type or diagnosis year. CONCLUSION: In the community, @entity5 constitutes 35% of @entity4 . The incidence of @entity4 has declined in recent years, and trends were similar for @entity5 and @entity3 , reaffirming a substantial decline in all acute manifestations of @entity2 . Survival after @entity4 did not change over time, but 30-day survival was worse for @entity3 compared with @entity5 .

title: Acute XXXX in the Community.

answer: @entity2


abstract: PURPOSE: An arthroscopic procedure for the treatment of @entity4 using platelet-derived growth factor (PDGF) carried out in a matrix of @entity5 was developed. This prospective, case-series-based study was designed to evaluate the safety and clinical utility of this procedure. METHODS: @entity0 with an isolated @entity4 larger than 5  mm long, 3  mm wide, and 5  mm deep and smaller than 30  mm long, 25  mm wide, or 20  mm deep were considered for enrolment. Only @entity0 with chronic lesions were enroled. Arthroscopic debridement was followed by the placement of recombinant @entity0 PDGF in a matrix of @entity5 . The @entity3 ( @entity3 ), visual analogue scale (VAS) for @entity2 , and SF-36 questionnaires were administered at 0, 2, 6, 12, and 24  weeks. Magnetic resonance imaging (MRI) and computed tomography (CT) scans were taken before and after surgery. RESULTS: Five @entity0 were ultimately enroled in this proof-of-concept trial. All outcome measures demonstrated marked improvement from baseline to final follow-up: The mean weight bearing VAS @entity2 score improved by 49  %, and the mean @entity3 functional score improved by 28  %. Bone healing was seen on CT, and reduction in @entity1 signal was seen on MRI. CONCLUSION: This new procedure may offer a promising alternative for the treatment of @entity4 . Further high-quality studies are needed to confirm these results and to analyse the long-term effects of the procedure. The clinical relevance of this study is that the procedure may provide a less invasive option with improved bone healing compared to standard techniques . LEVEL OF EVIDENCE: IV.

title: A study to evaluate the safety of platelet-derived growth factor for treatment of XXXX of the talus.

answer: @entity4


abstract: UNASSIGNED: Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with @entity1 relapse. @entity5 ( @entity5 ), a histone deacetylase inhibitor (HDACI), is currently being used in clinical trials of @entity0 . However, @entity5 facilitates the formation of induced pluripotent stem cells from somatic cells. We hypothesized that @entity5 would mediate the CSCs properties and subsequently confer a more malignant phenotype in @entity0 . Transfected @entity0 cells, which stably expresses a triple fused reporter gene (DsRedm-Fluc-tTKsr39) under the control of @entity3 promoter was used to establish a xenograft @entity2 model. After the treatment of @entity5 , H1299 cell line and @entity1 xenografts were sorted by fluorescence-activated cell sorting (FACS) based on aldehyde dehydrogenase (ALDH) activity. We found that @entity5 could suppress the growth of xenografted @entity1 with decreased proportion of @entity0 cells indicating that @entity5 may target CSCs. However, @entity5 significantly enhanced the @entity1 initiating capacity and the expression of malignant genes such as @entity4 , @entity7 and @entity6 in the remaining living ALDH(br) cells. These findings suggested that @entity5 treatment created a more drug-resistant state in residual ALDH(br) cells. The in vivo imaging technique may facilitate searching and characterization of CSCs.

title: Enhancement of @entity1 initiation and expression of @entity4 , @entity7 and XXXX genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

answer: @entity6


abstract: UNASSIGNED: Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with @entity1 relapse. @entity5 ( @entity5 ), a histone deacetylase inhibitor (HDACI), is currently being used in clinical trials of @entity0 . However, @entity5 facilitates the formation of induced pluripotent stem cells from somatic cells. We hypothesized that @entity5 would mediate the CSCs properties and subsequently confer a more malignant phenotype in @entity0 . Transfected @entity0 cells, which stably expresses a triple fused reporter gene (DsRedm-Fluc-tTKsr39) under the control of @entity3 promoter was used to establish a xenograft @entity2 model. After the treatment of @entity5 , H1299 cell line and @entity1 xenografts were sorted by fluorescence-activated cell sorting (FACS) based on aldehyde dehydrogenase (ALDH) activity. We found that @entity5 could suppress the growth of xenografted @entity1 with decreased proportion of @entity0 cells indicating that @entity5 may target CSCs. However, @entity5 significantly enhanced the @entity1 initiating capacity and the expression of malignant genes such as @entity4 , @entity7 and @entity6 in the remaining living ALDH(br) cells. These findings suggested that @entity5 treatment created a more drug-resistant state in residual ALDH(br) cells. The in vivo imaging technique may facilitate searching and characterization of CSCs.

title: Enhancement of @entity1 initiation and expression of @entity4 , XXXX and @entity6 genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

answer: @entity7


abstract: UNASSIGNED: Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with @entity1 relapse. @entity5 ( @entity5 ), a histone deacetylase inhibitor (HDACI), is currently being used in clinical trials of @entity0 . However, @entity5 facilitates the formation of induced pluripotent stem cells from somatic cells. We hypothesized that @entity5 would mediate the CSCs properties and subsequently confer a more malignant phenotype in @entity0 . Transfected @entity0 cells, which stably expresses a triple fused reporter gene (DsRedm-Fluc-tTKsr39) under the control of @entity3 promoter was used to establish a xenograft @entity2 model. After the treatment of @entity5 , H1299 cell line and @entity1 xenografts were sorted by fluorescence-activated cell sorting (FACS) based on aldehyde dehydrogenase (ALDH) activity. We found that @entity5 could suppress the growth of xenografted @entity1 with decreased proportion of @entity0 cells indicating that @entity5 may target CSCs. However, @entity5 significantly enhanced the @entity1 initiating capacity and the expression of malignant genes such as @entity4 , @entity7 and @entity6 in the remaining living ALDH(br) cells. These findings suggested that @entity5 treatment created a more drug-resistant state in residual ALDH(br) cells. The in vivo imaging technique may facilitate searching and characterization of CSCs.

title: Enhancement of @entity1 initiation and expression of XXXX , @entity7 and @entity6 genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

answer: @entity4


abstract: UNASSIGNED: Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with @entity1 relapse. @entity5 ( @entity5 ), a histone deacetylase inhibitor (HDACI), is currently being used in clinical trials of @entity0 . However, @entity5 facilitates the formation of induced pluripotent stem cells from somatic cells. We hypothesized that @entity5 would mediate the CSCs properties and subsequently confer a more malignant phenotype in @entity0 . Transfected @entity0 cells, which stably expresses a triple fused reporter gene (DsRedm-Fluc-tTKsr39) under the control of @entity3 promoter was used to establish a xenograft @entity2 model. After the treatment of @entity5 , H1299 cell line and @entity1 xenografts were sorted by fluorescence-activated cell sorting (FACS) based on aldehyde dehydrogenase (ALDH) activity. We found that @entity5 could suppress the growth of xenografted @entity1 with decreased proportion of @entity0 cells indicating that @entity5 may target CSCs. However, @entity5 significantly enhanced the @entity1 initiating capacity and the expression of malignant genes such as @entity4 , @entity7 and @entity6 in the remaining living ALDH(br) cells. These findings suggested that @entity5 treatment created a more drug-resistant state in residual ALDH(br) cells. The in vivo imaging technique may facilitate searching and characterization of CSCs.

title: Enhancement of XXXX initiation and expression of @entity4 , @entity7 and @entity6 genes in the adenocarcinoma of lung xenograft after vorinostat treatment.

answer: @entity1


abstract: UNASSIGNED: It is unclear whether osteoclasts are present and activated in @entity4 . We explored the expression of messenger RNA (mRNA) for osteoclast biomarkers and regulating factors in @entity6 to elucidate the level of osteoclast activity in this disease. Bone powder was collected from 14 @entity0 with cholesteatomatous and @entity2 media during tympanomastoidectomy, separately from cortical bone of the mastoid (clean bone powder), from bone neighboring @entity4 ( @entity1 ), and from bone of the air cells and antrum of @entity2 media @entity0 (noncholesteatomatous bone powder). The samples collected were soaked in TRIzol reagent, and total RNA was extracted and purified by the acid guanidinium thiocyanate-phenol-chloroform method, followed by the use of magnetic bead technology. The sample was then subjected to quantitative reverse transcription polymerase chain reaction for receptor activator of nuclear factor kB (RANK), tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), osteoclast-associated receptor ( @entity7 ), calcitonin receptor (CALCR), matrix metalloproteinase  9 (MMP9), receptor activator of nuclear factor kB ligand ( @entity5 ), and osteoprotegerin ( @entity3 ). There was no significant difference in the expression of TRAP, CTSK, @entity7 , CALCR, MMP9, or @entity3 among the clean, cholesteatomatous, and noncholesteatomatous bone powder. On the other hand, the expression of RANK and @entity5 was significantly lower in the @entity1 than in the noncholesteatomatous bone powder (P  =  0.003 and P  =  0.028, respectively). The @entity5 mRNA/ @entity3 mRNA ratio did not differ among the three samples. These results indicate that osteoclasts are unlikely to be activated in @entity4 . Bone resorption mechanisms not mediated by osteoclasts may need to be reappraised in @entity4 research in future studies.

title: Osteoclasts are not activated in XXXX .

answer: @entity6


abstract: Gastroparesis is a chronic disorder of @entity2 causing considerable suffering. We describe two cases of @entity4 which were treated by methods which were not part of routine conventional therapy, but which, nevertheless, led to significant clinical improvement. In the first case, the @entity0 suffered from @entity4 following a @entity1 while undergoing a lung transplant. During his illness a mega-bezoar formed, a well-described complication of @entity4 . After conservative measures failed, and in order to avoid a surgical intervention that carried considerable risk under the circumstances, a successful trial consisting of imbibing large amounts of "Coca Cola" and acupuncture was initiated. The bezoar dissolved completely and considerable improvement of the @entity0 's gastric motility was achieved. In the second case, the @entity0 was a young @entity0 suffering from @entity4 , which responded well to treatment with tricyclic antidepressants. Due to her intention to become pregnant, this treatment was discontinued and she was admitted to receive homeopathic treatment. After two failed attempts in finding the right homeopathic remedy to replace the conventional treatment, the third remedy (Sepia) used brought dramatic improvement in her general condition and her @entity3 . Today, over two years after her successful homeopathic treatment, she is in the middle of her second pregnancy, without any treatment and free of complaints. These two cases are examples of simple solutions for seemingly complicated and complex conditions alleviated by an integration of conventional and complementary/alternative medicine.

title: ["Do two walk together unless they have agreed to do so?"--Combining conventional and complementary medicine in the treatment of XXXX ].

answer: @entity4


abstract: UNASSIGNED: Aim This study assesses the feasibility of collecting genetic samples and self-reported outcome measures after cardiovascular risk assessment, and presenting the genetic test results to @entity0 . BACKGROUND: @entity2 ( @entity2 ) genetic tests are increasingly available through direct-to-consumer marketing, but their potential clinical impact on cardiovascular risk assessment is unclear. METHODS: Observational study in 10 British general practices in Central England. A total of 320 individuals, who had completed conventional cardiovascular risk assessment, were offered @entity2 genetic test, with follow-up outcome questionnaire at eight months for lifestyle change and State-Trait @entity1 . Findings A total of 119 (37%) @entity0 returned genetic test specimens, with over a third reporting family history of @entity2 in a specified relative; 79 (66.4%) were categorized above-average risk on conventional cardiovascular risk assessment, 65 of whom (82.3%) were only average risk on genetic assessment. The dietary fat questionnaire was poorly completed while study participation was not associated with increased @entity1 (mean increase in @entity1 score=2.1; 95% CI -0.1-4.3; P=0.06). CONCLUSION: As a feasibility study, over a third of individuals offered genetic testing in primary care, as part of CVD risk assessment, took up the offer. Although intervention did not appear to increase @entity1 , this needs further evaluation. To improve generalizability and effect size, future studies should actively engage individuals from wider socio-economic backgrounds who may not have already contemplated lifestyle change. The current research suggests general practitioners will face the clinical challenge of @entity0 presenting with direct-to-consumer genetic results that are inconsistent with conventional cardiovascular risk assessment.

title: Comparison of XXXX genetic assessment with conventional cardiovascular risk assessment in primary care: reflections on a feasibility study.

answer: @entity2


abstract: BACKGROUND: Little is known about the clinical and immunological changes in the nickel allergic @entity0 with systemic symptoms. We aimed to evaluate T helper cell responses of @entity0 with different clinical presentations due to nickel. METHODS: @entity0 having @entity1 and positive patch test results to nickel and 20 controls underwent skin prick tests with nickel. @entity6 , @entity10 , @entity4 and @entity5 were measured in the culture supernatants of PBMC stimulated by nickel during lymphocyte proliferation test (LTT). RESULTS: 69 @entity0 (56 female, mean age: 49.2    13.1), 97% having nickel containing dental devices and 20 controls (8 female, mean age 34.9    12.06) were evaluated. Skin prick tests with nickel were positive in 70% of the @entity0 (p<0.001), being significantly higher in the @entity0 with @entity2 / @entity3 (p=0.02). The LTT stimulation index (p<0.0001), @entity10 (p=0.002), @entity5 (p=0.01), @entity4 (p=0.04) and @entity6 (p=0.003) were higher in the @entity0 group. LTT stimulation index, @entity10 and @entity6 were significantly elevated in @entity0 having @entity2 , @entity3 and @entity7 when compared to those who had only oral symptoms or systemic @entity9 (p=0.004, p=0.002 and p=0.01, respectively). CONCLUSION: This study suggests the presence of @entity1 in addition to a Type IV immune reaction in @entity0 with chronic systemic symptoms related to nickel. Nickel containing @entity8 seem to trigger systemic symptoms in previously nickel sensitized @entity0 .

title: Oral nickel exposure may induce XXXX reaction in nickel-sensitized subjects.

answer: @entity1


abstract: BACKGROUND/PURPOSE: @entity3 due to @entity5 precludes percutaneous liver biopsy in many cases of @entity2 ( @entity2 ). The aim of this study was to assess the efficacy of @entity4 in correcting platelet counts (>100,000/mm(3)) to ensure percutaneous liver biopsy in @entity0 with @entity2 . METHODS: From January 2005 to December 2012, 51 consecutive @entity0 (mean age 11.5      3.0  years, 34 @entity0 ) with @entity2 who needed liver biopsy but could not be done due to @entity3 (platelets <100,000/mm(3) and/or total leukocyte counts <4,000/mm(3) with @entity1 ) were recruited and given a 4-week trial of long-acting @entity4 (1.5-2  mg/kg/day). Hemodynamic parameters and splenic artery hemodynamics by Doppler ultrasound were recorded before and after the @entity4 trial. Response to therapy was defined as improvement of platelet counts to >= 10(5)/mm(3). RESULTS: Thirty-two (62.7  %) @entity0 responded to @entity4 therapy and their mean platelet counts increased from 57.5      13.0  *  10(3) to 140.7      43.3  *  10(3)/mm(3), p  =  0.0001. Liver biopsy could be done in 29. While comparing responders with non-responders, baseline spleen size (7.4      3.3 vs. 12.7      4.5  cm, p  =  0.0001) and platelet counts (57.5      13.0  *  10(3) vs. 39.5      14.5  *  10(3), p  =  0.0001) were found to be significant. ROC curve suggested a cut-off value of  <=8.5  cm of spleen and >= 53,000 platelets as predictors of response. With @entity4 , mean arterial pressure and spleen size reduced (p  <  0.05) and splenic artery resistance increased significantly (p  =  0.005) in responders. CONCLUSIONS: @entity4 corrects @entity3 and makes liver biopsy possible in almost two-thirds of cases by reducing splenic sequestration through splenic artery vasoconstriction. The baseline spleen size and platelet counts determine the effectiveness of therapy. A trial of b-blocker is worth carrying out in cases where liver biopsy is contraindicated due to @entity3 .

title: b-Blocker therapy ameliorates XXXX due to portal hypertension in @entity0 .

answer: @entity5


abstract: BACKGROUND/PURPOSE: @entity3 due to @entity5 precludes percutaneous liver biopsy in many cases of @entity2 ( @entity2 ). The aim of this study was to assess the efficacy of @entity4 in correcting platelet counts (>100,000/mm(3)) to ensure percutaneous liver biopsy in @entity0 with @entity2 . METHODS: From January 2005 to December 2012, 51 consecutive @entity0 (mean age 11.5      3.0  years, 34 @entity0 ) with @entity2 who needed liver biopsy but could not be done due to @entity3 (platelets <100,000/mm(3) and/or total leukocyte counts <4,000/mm(3) with @entity1 ) were recruited and given a 4-week trial of long-acting @entity4 (1.5-2  mg/kg/day). Hemodynamic parameters and splenic artery hemodynamics by Doppler ultrasound were recorded before and after the @entity4 trial. Response to therapy was defined as improvement of platelet counts to >= 10(5)/mm(3). RESULTS: Thirty-two (62.7  %) @entity0 responded to @entity4 therapy and their mean platelet counts increased from 57.5      13.0  *  10(3) to 140.7      43.3  *  10(3)/mm(3), p  =  0.0001. Liver biopsy could be done in 29. While comparing responders with non-responders, baseline spleen size (7.4      3.3 vs. 12.7      4.5  cm, p  =  0.0001) and platelet counts (57.5      13.0  *  10(3) vs. 39.5      14.5  *  10(3), p  =  0.0001) were found to be significant. ROC curve suggested a cut-off value of  <=8.5  cm of spleen and >= 53,000 platelets as predictors of response. With @entity4 , mean arterial pressure and spleen size reduced (p  <  0.05) and splenic artery resistance increased significantly (p  =  0.005) in responders. CONCLUSIONS: @entity4 corrects @entity3 and makes liver biopsy possible in almost two-thirds of cases by reducing splenic sequestration through splenic artery vasoconstriction. The baseline spleen size and platelet counts determine the effectiveness of therapy. A trial of b-blocker is worth carrying out in cases where liver biopsy is contraindicated due to @entity3 .

title: b-Blocker therapy ameliorates @entity5 due to portal hypertension in XXXX .

answer: @entity0


abstract: OBJECTIVES: To investigate the effect of interstitial Cajal-like cells (ICLCs) on contraction of gallbladder muscle strips; and to analyze the changes of ICLCs during cholesterol @entity2 formation in @entity0 . METHODS: The cholesterol @entity2 animal model was made by feeding @entity0 with @entity3 ( @entity3 ). In vitro isolated gallbladder muscle strips were prepared. Gallbladder motility was assessed by the contraction frequency and amplitude of slow wave in response to CCK-8. The alteration in ICLC density was estimated by using immunohistochemistry. The expression of c-kit and stem cell factor (SCF) were determined. RESULTS AND CONCLUSIONS: The amplitude and frequency of slow wave was significantly lower in gallbladder muscle strips with the impaired ICLCs. And it is correlated with the decreased contractile response to CCK-8. In @entity3 @entity0 , the ICLC density and bile flow in response to CCK-8 were remarkably decreased. The results indicated that gallbladder ICLCs can create slow wave potential, and also get involved in the regulation of CCK-8 induced gallbladder smooth muscle motility. In the process of cholesterol @entity2 formation, ICLC density clearly decreased. This further @entity1 . The decrease in ICLC density may result from decreased expression of c-kit and SCF during cholesterol @entity2 formation.

title: The role of interstitial Cajal-like cells in the formation of cholesterol stones in XXXX gallbladder.

answer: @entity0


abstract: BACKGROUND: The distal part of the humerus is the second most common @entity3 location in @entity0 . Complications are more common than with other pediatric @entity3 and are mostly related to inappropriate diagnosis and treatment. METHODS: On the basis of data from 1990 through 2010 in the national registry of inpatient care treatment in Finland, we calculated the number of @entity0 less than seventeen years of age who were treated under anesthesia for a @entity3 (reduction with or without internal fixation) and the number of treatment institutions. We analyzed compensation claims concerning the treatment of these @entity3 that were received by the @entity0 Insurance Centre. The risk of a complication of treatment and the number of avoidable complications of treatment were assessed. RESULTS: A total of 7909 @entity0 underwent a procedure under anesthesia to treat a @entity3 . Claims were filed for 117 @entity0 (118 @entity3 , including seventy-four supracondylar, nineteen epicondylar, nineteen condylar, and six T-type), and compensation was granted for eighty-three (71%) of the @entity0 . @entity1 (forty-nine), delayed treatment (twenty), @entity2 (seventeen), and @entity4 (seven) were the most common reasons for compensation. On reevaluation of the claims, ninety @entity0 were assessed as having had complications of treatment. In our opinion, complications could have been avoided for eighty-six (96%) of these @entity0 . CONCLUSIONS: We believe that improving the quality of primary assessment and operative technique would decrease the number of complications in the treatment of @entity3 . Centralizing operative treatment to tertiary hospitals should be considered. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

title: XXXX and complications of treatment in Finland: a review of compensation claims from 1990 through 2010.

answer: @entity3


abstract: PURPOSE: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with @entity3 . In this phase I/II study, efficacy and safety of the combination were explored in @entity0 with @entity1 ( @entity1 ). EXPERIMENTAL DESIGN: A phase I study in @entity0 with clear cell @entity1 and any prior number of therapies was conducted using a classical 3 + 3 design to evaluate standard doses of @entity3 with increasing doses of BNC105P. At the recommended phase II dose (RP2D), @entity0 with clear cell @entity1 and one to two prior therapies (including >=  1 VEGF-TKI) were randomized to BNC105P with @entity3 (arm A) or @entity3 alone (arm B). The primary endpoint of the study was 6-month progression-free survival (6MPFS). Secondary endpoints included response rate, PFS, overall survival, and exploratory biomarker analyses. RESULTS: In the phase I study (N = 15), a dose of BNC105P at 16 mg/m(2) with @entity3 at 10 mg daily was identified as the RP2D. In the phase II study, 139 @entity0 were randomized, with 69 and 67 evaluable @entity0 in arms A and B, respectively. 6MPFS was similar in the treatment arms (arm A: 33.82% vs. arm B: 30.30%, P = 0.66) and no difference in median PFS was observed (arm A: 4.7 mos vs. arm B: 4.1 mos; P = 0.49). Changes in @entity2 , @entity4 , sex hormone-binding globulin, and serum amyloid A protein were associated with clinical outcome with BNC105P. CONCLUSIONS: Although the primary endpoint was not met in an unselected population, correlative studies suggest several biomarkers that warrant further prospective evaluation. Clin Cancer Res; 1-8.   2015 AACR.

title: A Phase I/II Trial of BNC105P with @entity3 in XXXX .

answer: @entity1


abstract: PURPOSE: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with @entity3 . In this phase I/II study, efficacy and safety of the combination were explored in @entity0 with @entity1 ( @entity1 ). EXPERIMENTAL DESIGN: A phase I study in @entity0 with clear cell @entity1 and any prior number of therapies was conducted using a classical 3 + 3 design to evaluate standard doses of @entity3 with increasing doses of BNC105P. At the recommended phase II dose (RP2D), @entity0 with clear cell @entity1 and one to two prior therapies (including >=  1 VEGF-TKI) were randomized to BNC105P with @entity3 (arm A) or @entity3 alone (arm B). The primary endpoint of the study was 6-month progression-free survival (6MPFS). Secondary endpoints included response rate, PFS, overall survival, and exploratory biomarker analyses. RESULTS: In the phase I study (N = 15), a dose of BNC105P at 16 mg/m(2) with @entity3 at 10 mg daily was identified as the RP2D. In the phase II study, 139 @entity0 were randomized, with 69 and 67 evaluable @entity0 in arms A and B, respectively. 6MPFS was similar in the treatment arms (arm A: 33.82% vs. arm B: 30.30%, P = 0.66) and no difference in median PFS was observed (arm A: 4.7 mos vs. arm B: 4.1 mos; P = 0.49). Changes in @entity2 , @entity4 , sex hormone-binding globulin, and serum amyloid A protein were associated with clinical outcome with BNC105P. CONCLUSIONS: Although the primary endpoint was not met in an unselected population, correlative studies suggest several biomarkers that warrant further prospective evaluation. Clin Cancer Res; 1-8.   2015 AACR.

title: A Phase I/II Trial of BNC105P with XXXX in @entity1 .

answer: @entity3


abstract: BACKGROUND: Alaska Native @entity0 currently have a higher prevalence of @entity1 than do nonnative Alaskans, although in the 1950s @entity1 was rare among Alaska Native @entity0 . A novel biomarker of marine foods, the @entity4 isotope ratio (  @entity7 ) in RBCs was shown to be negatively associated with @entity2 . Few studies have examined how individual characteristics modify the association of marine food intake with blood pressure. OBJECTIVE: This exploratory analysis examines whether sex, adiposity, and @entity1 modify the inverse association between marine food intake and blood pressure. METHODS: We used covariate-adjusted linear models to describe the association between   @entity7 and blood pressure in 873 adult Alaska Native (Yup'ik) @entity0 who resided in 8 communities in southwest Alaska. We separately stratified by sex, body mass index (BMI) group, @entity3 , and @entity1 status and assessed the interaction between   @entity7 and @entity0 characteristics on blood pressure via likelihood ratio tests. RESULTS: The association between   @entity7 and systolic blood pressure was modified by sex, BMI status, and @entity3 , with the inverse association observed only in the male (b = -1.5; 95% CI: -2.4, -0.6 : , nonobese BMI (b = -1.7; 95% CI: -2.5, -1.0), and @entity3 (b = -1.6; 95% CI: -2.4, -0.9) strata (all P-interaction < 0.0001). A reduction in diastolic blood pressure associated with   @entity7 was observed in the nonobese BMI (b = -1.1; 95% CI: -1.7, -0.5) and @entity3 (b = -1.1; 95% CI: -1.7, -0.5) strata, although only the interaction between BMI group and   @entity7 with diastolic blood pressure was significant. The inverse association between   @entity7 and both @entity2 was observed in nonhypertensive individuals, although the comparison had limited power. The results were consistent with those identified by using combined RBC concentrations of @entity6 and @entity5 as the biomarker of marine food intake, although the associations identified by using   @entity7 were larger. CONCLUSIONS: Obesity status modified the inverse association between marine food intake and both @entity2 in adult Alaska Native (Yup'ik) @entity0 . The inverse association between   @entity7 and systolic blood pressure was also modified by sex.

title: Sex, Adiposity, and XXXX Status Modify the Inverse Effect of Marine Food Intake on Blood Pressure in Alaska Native (Yup'ik) @entity0 .

answer: @entity1


abstract: BACKGROUND: Alaska Native @entity0 currently have a higher prevalence of @entity1 than do nonnative Alaskans, although in the 1950s @entity1 was rare among Alaska Native @entity0 . A novel biomarker of marine foods, the @entity4 isotope ratio (  @entity7 ) in RBCs was shown to be negatively associated with @entity2 . Few studies have examined how individual characteristics modify the association of marine food intake with blood pressure. OBJECTIVE: This exploratory analysis examines whether sex, adiposity, and @entity1 modify the inverse association between marine food intake and blood pressure. METHODS: We used covariate-adjusted linear models to describe the association between   @entity7 and blood pressure in 873 adult Alaska Native (Yup'ik) @entity0 who resided in 8 communities in southwest Alaska. We separately stratified by sex, body mass index (BMI) group, @entity3 , and @entity1 status and assessed the interaction between   @entity7 and @entity0 characteristics on blood pressure via likelihood ratio tests. RESULTS: The association between   @entity7 and systolic blood pressure was modified by sex, BMI status, and @entity3 , with the inverse association observed only in the male (b = -1.5; 95% CI: -2.4, -0.6 : , nonobese BMI (b = -1.7; 95% CI: -2.5, -1.0), and @entity3 (b = -1.6; 95% CI: -2.4, -0.9) strata (all P-interaction < 0.0001). A reduction in diastolic blood pressure associated with   @entity7 was observed in the nonobese BMI (b = -1.1; 95% CI: -1.7, -0.5) and @entity3 (b = -1.1; 95% CI: -1.7, -0.5) strata, although only the interaction between BMI group and   @entity7 with diastolic blood pressure was significant. The inverse association between   @entity7 and both @entity2 was observed in nonhypertensive individuals, although the comparison had limited power. The results were consistent with those identified by using combined RBC concentrations of @entity6 and @entity5 as the biomarker of marine food intake, although the associations identified by using   @entity7 were larger. CONCLUSIONS: Obesity status modified the inverse association between marine food intake and both @entity2 in adult Alaska Native (Yup'ik) @entity0 . The inverse association between   @entity7 and systolic blood pressure was also modified by sex.

title: Sex, Adiposity, and @entity1 Status Modify the Inverse Effect of Marine Food Intake on Blood Pressure in Alaska Native (Yup'ik) XXXX .

answer: @entity0


abstract: The investigation was designed to study plasma drug concentration and prolactin response determined by two different doses of @entity3 , a standard one and four-fold higher the other, and to explore the relationships between clinical effects and pharmacokinetic and physiological variables in @entity1 @entity0 . 24 @entity1 @entity0 received @entity3 during 40 consecutive days. During the first 10 days they received 0,25 mg/kg b.w. During the next 20 days they were given 1 mg/kg b.w. Finally they received 0,25 mg/kg b.w. during the last ten days. The @entity0 were clinically assessed and plasma @entity3 and prolactin concentrations were determined on days 0, 5, 10, 20, 30 and 40. In the range of dose studied, the use of higher than conventional doses of @entity3 results in an increased concentration in the cellular site of action and in a more complete blockade of central @entity2 receptors. Prolactin response was positive correlated with serum @entity3 concentration. Clinical remission was not direct correlated, neither with serum neuroleptic concentration nor with prolactin level. Those @entity0 who reached higher levels of plasmatic neuroleptic and prolactin concentrations were more susceptible to develop severe extrapyramidal side-effects. Pharmacokinetic and pharmacodynamic monitoring of neuroleptic treatment could be useful to identify these @entity0 .

title: [Standard and high doses of XXXX . Clinical, pharmacokinetic and pharmacodynamic aspects].

answer: @entity3


abstract: The growth of 9A and 7316A Morris @entity2 was studied in @entity3 (PN)-depleted and in pair-fed control @entity1 . @entity1 groups were fed the respective diets for 3 weeks, inoculated with 9A and 7316A @entity0 cells in both hind leg muscles, and killed after 21 and 41 days respectively. Another group was fed ad lib the PN-sufficient diet and similarly inoculated with 7777 @entity2 cells. In this instance @entity0 were let grow maximally to the extent that @entity1 were practically unable to move and feed themselves. At this time ten animals were treated with @entity4 every other day for 9 days, leaving five (untreated) @entity1 as controls. @entity1 pair-fed the PN-sufficient diet developed significantly heavier 9A and 7316A @entity2 with P less than or equal to 0.005 and P less than 0.001 significance levels, respectively. Treatment with the antivitamin agent extended significantly animal life span. Six @entity1 lived for 8 days, three for 12, and one for 18 days. Four of the untreated @entity1 died within 3 days, the fifth on the 8th day. These results demonstrate that PN restriction causes significant @entity0 weight and its in situ inactivation in vivo significantly extends the life of the @entity0 bearing animals.

title: Control of XXXX growth by @entity3 restriction or treatment with an antivitamin agent.

answer: @entity0


abstract: The growth of 9A and 7316A Morris @entity2 was studied in @entity3 (PN)-depleted and in pair-fed control @entity1 . @entity1 groups were fed the respective diets for 3 weeks, inoculated with 9A and 7316A @entity0 cells in both hind leg muscles, and killed after 21 and 41 days respectively. Another group was fed ad lib the PN-sufficient diet and similarly inoculated with 7777 @entity2 cells. In this instance @entity0 were let grow maximally to the extent that @entity1 were practically unable to move and feed themselves. At this time ten animals were treated with @entity4 every other day for 9 days, leaving five (untreated) @entity1 as controls. @entity1 pair-fed the PN-sufficient diet developed significantly heavier 9A and 7316A @entity2 with P less than or equal to 0.005 and P less than 0.001 significance levels, respectively. Treatment with the antivitamin agent extended significantly animal life span. Six @entity1 lived for 8 days, three for 12, and one for 18 days. Four of the untreated @entity1 died within 3 days, the fifth on the 8th day. These results demonstrate that PN restriction causes significant @entity0 weight and its in situ inactivation in vivo significantly extends the life of the @entity0 bearing animals.

title: Control of @entity0 growth by XXXX restriction or treatment with an antivitamin agent.

answer: @entity3


abstract: BACKGROUND: The pathological mechanisms underlying @entity2 in @entity1 ( @entity1 ) are not yet fully understood and, in addition to demyelinating lesions and gray-matter @entity4 , subclinical disease activity may play a role. OBJECTIVE: To evaluate the contribution of asymptomatic @entity5 -enhancing lesions to @entity2 along with gray-matter damage and @entity4 in @entity6 ( @entity6 ) @entity0 . METHODS: Forty-two treated @entity6 and 30 controls were evaluated. MRI (3T) variables of interest were brain white-matter and cortical lesion load, cortical and deep gray-matter volumes, corpus callosum volume and presence of @entity5 -enhancing lesions. Outcome variables included EDSS, @entity1 Functional Composite (MSFC) subtests and the Brief Repeatable Battery of Neuropsychological tests. @entity2 was classified as deficits in two or more cognitive subtests. Multivariate regression analyses assessed the contribution of MRI metrics to outcomes. RESULTS: @entity0 with @entity2 (45.2%) had more @entity3 and lower gray-matter and callosal volumes. @entity0 with subclinical MRI activity (15%) had worse cognitive performance. Clinical disability on MSFC was mainly associated with putaminal @entity4 . The main independent predictors for @entity2 were high burden of @entity3 and number of @entity5 -enhancing lesions. CONCLUSIONS: @entity2 was especially related to high burden of @entity3 and subclinical disease activity. Cognitive studies in @entity1 should look over subclinical disease activity as a potential contributor to @entity2 .

title: Subclinical MRI disease activity influences cognitive performance in XXXX @entity0 .

answer: @entity1


abstract: BACKGROUND: The pathological mechanisms underlying @entity2 in @entity1 ( @entity1 ) are not yet fully understood and, in addition to demyelinating lesions and gray-matter @entity4 , subclinical disease activity may play a role. OBJECTIVE: To evaluate the contribution of asymptomatic @entity5 -enhancing lesions to @entity2 along with gray-matter damage and @entity4 in @entity6 ( @entity6 ) @entity0 . METHODS: Forty-two treated @entity6 and 30 controls were evaluated. MRI (3T) variables of interest were brain white-matter and cortical lesion load, cortical and deep gray-matter volumes, corpus callosum volume and presence of @entity5 -enhancing lesions. Outcome variables included EDSS, @entity1 Functional Composite (MSFC) subtests and the Brief Repeatable Battery of Neuropsychological tests. @entity2 was classified as deficits in two or more cognitive subtests. Multivariate regression analyses assessed the contribution of MRI metrics to outcomes. RESULTS: @entity0 with @entity2 (45.2%) had more @entity3 and lower gray-matter and callosal volumes. @entity0 with subclinical MRI activity (15%) had worse cognitive performance. Clinical disability on MSFC was mainly associated with putaminal @entity4 . The main independent predictors for @entity2 were high burden of @entity3 and number of @entity5 -enhancing lesions. CONCLUSIONS: @entity2 was especially related to high burden of @entity3 and subclinical disease activity. Cognitive studies in @entity1 should look over subclinical disease activity as a potential contributor to @entity2 .

title: Subclinical MRI disease activity influences cognitive performance in @entity1 XXXX .

answer: @entity0


abstract: BACKGROUND: Because atypical @entity4 (ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long-term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of @entity0 are now long-term survivors. PROCEDURE: Retrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry. RESULTS: Among 77 @entity0 diagnosed between 1995-2012, 16(22%) were survivors. Formal NP assessments were available in eight @entity0 . Partial information on academic achievement was available on three additional @entity0 . There were four @entity0 and seven @entity0 diagnosed at a median age of 27.5 months. Seven @entity0 underwent complete resection and three had @entity1 . All but one received sequential high dose chemotherapy. Five @entity0 received intrathecal chemotherapy. Three @entity0 underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9-9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50-119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed @entity0 (median time assessment from diagnosis 2.6 years (1.6-4.7)) had average to high average FSIQ, @entity3 . Five other @entity0 diagnosed earlier and tested at a median time of 4.9 years (3.3-8.3) post-diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range. CONCLUSION: Overall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation. Pediatr @entity2    2015 Wiley Periodicals, Inc.

title: Neurocognitive evaluation of long term survivors of atypical XXXX (ATRT): The Canadian registry experience.

answer: @entity4


abstract: @entity1 ( @entity1 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity6 - or @entity5 -anesthetized male @entity0 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity2 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1 caused a dose-related increase in GH and SRIF. In another study, @entity7 (5 or 20 mg) was injected ip into @entity6 -anesthetized @entity0 . @entity7 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity3 ( @entity4 ) injected ip into @entity6 - or @entity5 -anesthetized @entity0 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity4 -induced serum GH increase and in hypothalamic SRIF in @entity5 -anesthetized @entity0 . These results show that @entity1 and @entity4 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1 or @entity4 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity4 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity4 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.

title: Concomitant increases in serum growth hormone and hypothalamic XXXX in @entity0 after injection of @entity1 , @entity7 , or @entity3 .

answer: @entity2


abstract: @entity1 ( @entity1 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity6 - or @entity5 -anesthetized male @entity0 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity2 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1 caused a dose-related increase in GH and SRIF. In another study, @entity7 (5 or 20 mg) was injected ip into @entity6 -anesthetized @entity0 . @entity7 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity3 ( @entity4 ) injected ip into @entity6 - or @entity5 -anesthetized @entity0 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity4 -induced serum GH increase and in hypothalamic SRIF in @entity5 -anesthetized @entity0 . These results show that @entity1 and @entity4 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1 or @entity4 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity4 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity4 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.

title: Concomitant increases in serum growth hormone and hypothalamic @entity2 in @entity0 after injection of @entity1 , XXXX , or @entity3 .

answer: @entity7


abstract: @entity1 ( @entity1 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity6 - or @entity5 -anesthetized male @entity0 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity2 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1 caused a dose-related increase in GH and SRIF. In another study, @entity7 (5 or 20 mg) was injected ip into @entity6 -anesthetized @entity0 . @entity7 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity3 ( @entity4 ) injected ip into @entity6 - or @entity5 -anesthetized @entity0 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity4 -induced serum GH increase and in hypothalamic SRIF in @entity5 -anesthetized @entity0 . These results show that @entity1 and @entity4 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1 or @entity4 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity4 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity4 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.

title: Concomitant increases in serum growth hormone and hypothalamic @entity2 in XXXX after injection of @entity1 , @entity7 , or @entity3 .

answer: @entity0


abstract: @entity1 ( @entity1 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity6 - or @entity5 -anesthetized male @entity0 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity2 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1 caused a dose-related increase in GH and SRIF. In another study, @entity7 (5 or 20 mg) was injected ip into @entity6 -anesthetized @entity0 . @entity7 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity3 ( @entity4 ) injected ip into @entity6 - or @entity5 -anesthetized @entity0 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity4 -induced serum GH increase and in hypothalamic SRIF in @entity5 -anesthetized @entity0 . These results show that @entity1 and @entity4 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1 or @entity4 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity4 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity4 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.

title: Concomitant increases in serum growth hormone and hypothalamic @entity2 in @entity0 after injection of @entity1 , @entity7 , or XXXX .

answer: @entity3


abstract: @entity1 ( @entity1 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity6 - or @entity5 -anesthetized male @entity0 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity2 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1 caused a dose-related increase in GH and SRIF. In another study, @entity7 (5 or 20 mg) was injected ip into @entity6 -anesthetized @entity0 . @entity7 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity3 ( @entity4 ) injected ip into @entity6 - or @entity5 -anesthetized @entity0 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity4 -induced serum GH increase and in hypothalamic SRIF in @entity5 -anesthetized @entity0 . These results show that @entity1 and @entity4 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1 or @entity4 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity4 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity4 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.

title: Concomitant increases in serum growth hormone and hypothalamic @entity2 in @entity0 after injection of XXXX , @entity7 , or @entity3 .

answer: @entity1


abstract: UNASSIGNED: The functional diversity of eukaryotic viruses infecting a single host strain from seawater samples originating from distant marine locations is unknown. To estimate this diversity, we used lysis plaque assays to detect viruses that infect the widespread species @entity2 , which is found in coastal and mesotrophic systems, and @entity1 , which was isolated from coastal and lagoon sites from the NW Mediterranean Sea. Detection of viral lytic activities against @entity1 was not observed using seawater from most sites, except those close to the area where the host strain was isolated. In contrast, the more cosmopolitan @entity2 species recovered viruses from locations in the Atlantic and Pacific Oceans and the Mediterranean Sea. Six new @entity2 viruses (OlVs) were then characterized and their genomes sequenced. Two subgroups of OlVs were distinguished based on their genetic distances and on the inversion of a central 32 kb long DNA fragment, but overall their genomes displayed a high level of synteny. The two groups did not correspond to proximity of isolation sites and the phylogenetic distance between these subgroups was higher than the distances observed among viruses infecting @entity1 . Our study demonstrates that viruses originating from very distant sites are able to infect the same algal host strain and can be more diverse than those infecting different species of the same genus. Finally, distinctive features and evolutionary distances between these different viral subgroups does not appear to be linked to biogeography of the viral isolates. IMPORTANCE: Marine eukaryotic phytoplankton virus diversity has yet to be addressed and, more specifically, it is unclear whether diversity is connected to geographical distance and whether @entity0 and lysis patterns exist among such viruses that infect the same host strain. Here, we assessed the genetic distance of geographically segregated viruses that infect the ubiquitous green microalga @entity1 . This study provides the first glimpse into the diversity of predicted gene functions in @entity1 viruses originating from distant sites and provide new insights to potential host-distributions and restrictions in the world oceans.

title: Diversity of viruses infecting the green micro-alga XXXX .

answer: @entity2


abstract: OBJECTIVES: @entity1 and @entity5 are associated with increased @entity2 and oxidative stress in the placenta. With @entity5 greater @entity2 , @entity4 and apoptosis were found in placentas of male vs female placentas. We find increased @entity11 expression, and associated decreased placental mitochondrial function with severe @entity5 . We investigated if the inflammatory transcription factors @entity9 and NFkB regulate placental @entity11 expression in a sexually dimorphic manner. METHODS: Placentas were collected at term (C section, no labor) from healthy lean @entity0 (n=6 each sex) and trophoblast cultures prepared. Trophoblasts were treated with @entity3 (10ng/ml, 2h) and expression of @entity11 , @entity9 , NFkB and mitochondrial function measured. RESULTS: @entity3 treatment significantly increased placental NFkB @entity10 expression in both sexes but @entity7 ( @entity7 ) only in female placentas. This was accompanied by significantly increased binding of @entity7 to the @entity12 promoter and increased @entity11 expression only in female placentas. Correspondingly significantly decreased expression of the @entity11 mitochondrial target proteins @entity8 cluster assembly proteins and @entity6 dehydrogenase 1a subcomplex 4 was found in the female placentas treated with @entity3 together with a significant reduction in mitochondrial respiration. Inhibition of @entity7 by siRNA abolished the effect of @entity3 on @entity11 expression and mitochondrial respiration in the female placenta. CONCLUSIONS: We find sexual dimorphism in the effect of @entity2 on placental @entity11 expression perhaps mediated by the @entity7 pathway. This may link placental @entity2 in @entity5 to decreased mitochondrial function in pregnancies with a female fetus. DISCLOSURES: L. Myatt: None. C. Guo: None. S. Muralimanoharan: None. A. Maloyan: None.

title: [38-OR]: Sexual dimorphism in the effect of @entity2 on trophoblast function with XXXX .

answer: @entity5


abstract: OBJECTIVES: @entity1 and @entity5 are associated with increased @entity2 and oxidative stress in the placenta. With @entity5 greater @entity2 , @entity4 and apoptosis were found in placentas of male vs female placentas. We find increased @entity11 expression, and associated decreased placental mitochondrial function with severe @entity5 . We investigated if the inflammatory transcription factors @entity9 and NFkB regulate placental @entity11 expression in a sexually dimorphic manner. METHODS: Placentas were collected at term (C section, no labor) from healthy lean @entity0 (n=6 each sex) and trophoblast cultures prepared. Trophoblasts were treated with @entity3 (10ng/ml, 2h) and expression of @entity11 , @entity9 , NFkB and mitochondrial function measured. RESULTS: @entity3 treatment significantly increased placental NFkB @entity10 expression in both sexes but @entity7 ( @entity7 ) only in female placentas. This was accompanied by significantly increased binding of @entity7 to the @entity12 promoter and increased @entity11 expression only in female placentas. Correspondingly significantly decreased expression of the @entity11 mitochondrial target proteins @entity8 cluster assembly proteins and @entity6 dehydrogenase 1a subcomplex 4 was found in the female placentas treated with @entity3 together with a significant reduction in mitochondrial respiration. Inhibition of @entity7 by siRNA abolished the effect of @entity3 on @entity11 expression and mitochondrial respiration in the female placenta. CONCLUSIONS: We find sexual dimorphism in the effect of @entity2 on placental @entity11 expression perhaps mediated by the @entity7 pathway. This may link placental @entity2 in @entity5 to decreased mitochondrial function in pregnancies with a female fetus. DISCLOSURES: L. Myatt: None. C. Guo: None. S. Muralimanoharan: None. A. Maloyan: None.

title: [38-OR]: Sexual dimorphism in the effect of XXXX on trophoblast function with @entity5 .

answer: @entity2


abstract: OBJECTIVES: This study was conducted assess the relation between alteration of the @entity3 profile and plasma albumin in @entity2 . METHODS: We performed a cross sectional study using 10 @entity0 with @entity2 albumin    3gr/dL and 9 @entity0 with @entity2 albumin >3gr/dL. Plasma albumin was analyzed by photometric using Dyalis reagent, and plasma @entity3 were analyzed by ion exchange chromatography (IEC). RESULTS: There were alterations of @entity3 in @entity0 with an albumin    3 gr/dL compare with those with an albumin >3gr/dL. Essential @entity3 and non-essential @entity3 were significantly different (Hotteling T0.05). Regression analysis revealed that 94% of the alteration of 10 @entity3 influenced albumin concentration. CONCLUSIONS: Alteration of the plasma @entity1 profile influenced albumin concentration in @entity2 . Plasma albumin changes were influenced by more than one @entity3 rather than single. DISCLOSURES: A. Aditiawarman: None. E.G. Dachlan: None.

title: [102-POS] : Alteration of the plasma @entity1 profile in XXXX with hypoalbuminemia.

answer: @entity2


abstract: OBJECTIVES: This study was conducted assess the relation between alteration of the @entity3 profile and plasma albumin in @entity2 . METHODS: We performed a cross sectional study using 10 @entity0 with @entity2 albumin    3gr/dL and 9 @entity0 with @entity2 albumin >3gr/dL. Plasma albumin was analyzed by photometric using Dyalis reagent, and plasma @entity3 were analyzed by ion exchange chromatography (IEC). RESULTS: There were alterations of @entity3 in @entity0 with an albumin    3 gr/dL compare with those with an albumin >3gr/dL. Essential @entity3 and non-essential @entity3 were significantly different (Hotteling T0.05). Regression analysis revealed that 94% of the alteration of 10 @entity3 influenced albumin concentration. CONCLUSIONS: Alteration of the plasma @entity1 profile influenced albumin concentration in @entity2 . Plasma albumin changes were influenced by more than one @entity3 rather than single. DISCLOSURES: A. Aditiawarman: None. E.G. Dachlan: None.

title: [102-POS] : Alteration of the plasma XXXX profile in @entity2 with hypoalbuminemia.

answer: @entity1


abstract: OBJECTIVES: Preeclampsia is a @entity1 disorder of pregnancy known to increase the risk of @entity0 in both mothers and offspring later in life. Offspring exposed to a suboptimal intrauterine environment during critical periods of growth may experience altered fetal programming and subsequent long term cardiovascular changes. The aim of this study was to investigate changes in vascular response in offspring from experimental preeclamptic (EPE) compared to normotensive @entity4 pregnancies (controls), following a high salt diet challenge. METHODS: After one week of baseline measurements on a standard diet, animals were fed a high salt diet for two weeks. @entity2 (SBP, @entity5 ) were measured and urinary @entity3 assessed in offspring from EPE (n=6) and controls (n=6). A generalized linear model was performed to compare BP between the two groups at both baseline and day 14, adjusted for current age. Data is reported as the mean  standard error. Significance was set at P<0.05. RESULTS: At baseline there were no differences between the groups for SBP (P=0.89) and @entity5 (P=0.38). After salt loading the EPE group had significantly higher SBP (92  5mmHg) compared to the control group (83  4 mmHg, P=0.03). There was no significant difference in @entity5 between the two groups (P=0.10). There was no difference in urinary @entity3 excretion between groups (average for both groups 30mmol/day). CONCLUSIONS: Offspring from EPE pregnancies had significantly higher blood pressure after a two week salt challenge, compared with controls. Salt sensitivity may differ in offspring from @entity1 pregnancies due to fetal programming. This could have long term consequences for cardiovascular health of EPE offspring. Further research is required to determine exact mechanisms. DISCLOSURES: K.R. Yeung: None. S.M. Lim: None. S. Heffernan: None. S. Pears: None. J.M. Lind: None. A. Hennessy: None. A. Makris: None.

title: [110-POS] : Salt sensitivity in the offspring of experimental preeclamptic and normotensive XXXX pregnancies.

answer: @entity4


abstract: OBJECTIVES: To examine the feasibility of a randomized trial to determine whether oral regimens of nifedipine, labetalol or methyldopa are effective for acute control of severe @entity1 in pregnancy. METHODS: In an open label pilot study, 30 pregnant @entity0 in India with a sustained @entity3    160mmHg or dBP    110mmHg were assigned sequentially to receive oral nifedipine (10mg up to 3 total doses in 6h) (n=10), oral labetalol (200mg up to 3 total doses in 6h) (n=10), or a single dose of oral methyldopa 1000mg (n=10) until the target blood pressure of 130-150mmHg systolic and 80-100mmHg diastolic was achieved. The primary endpoint of the study was achievement of the targeted blood pressure within 6h without an adverse outcome. Secondary outcomes were use of additional antihypertensives, adverse maternal and neonatal effects, and side effect profile. RESULTS: Most @entity0 achieved the target blood pressure within 6h without use of additional agents or adverse outcomes (nifedipine: 8/10; labetalol: 9/10; methyldopa: 5/10). Five in the methyldopa arm received additional medication for @entity1 ; 2 with successful control and 3 unsuccessful. One in the nifedipine arm received additional medication for @entity2 . Most @entity0 in the nifedipine arm (9/10) became tachycardic (pulse>105) at one or more monitoring visits. No serious adverse maternal or perinatal side effects occurred. CONCLUSIONS: Oral regimens of nifedipine, labetalol and methyldopa are potentially effective justifying a randomized trial of all three medications with the current dosing regimens. Findings were used to adjust operational design of the trial. DISCLOSURES: T. Easterling: None. H. Bracken: None. S. Mundle: None. L. Magee: None. P. vonDadelszen: None. B. Winikoff: None.

title: [238-POS]: Oral antihypertensive regimens for management of severe XXXX in pregnancy: Results from a pilot study in India.

answer: @entity1


abstract: Aggressive surgical resection is the primary therapy for @entity1 . However, aggressive resection may compromise functional healthy brain tissue. Currently, there are no objective cues for surgeons to distinguish healthy tissue from @entity0 and determine @entity0 borders; surgeons skillfully rely on subjective means such as tactile feedback. This often results in incomplete resection and recurrence. The objective of the present study was to design, develop, and evaluate, in vitro and in vivo, a nanoencapsulated visible dye for intraoperative, @entity3 margins in an invasive @entity0 model. Liposomal nanocarriers containing @entity4 (nano-EB) were developed, characterized, and tested for safety in vitro and in vivo. 3RT1 @entity2 A @entity1 cells were implanted into brains of Fischer 344 @entity2 . Nano-EB or EB solution was injected via tail vein into @entity0 -bearing animals. To assess @entity0 staining, tissue samples were analyzed visibly and using fluorescence microscopy. Area, perimeter ratios, and Manders overlap coefficients were calculated to quantify extent of staining. Nano-EB clearly marked @entity0 margins in the invasive @entity0 model. Area ratio of nano-EB staining to @entity0 was 0.89        0.05, perimeter ratio was 0.94        0.04, Manders R was 0.51        0.08, and M1 was 0.97        0.06. @entity0 border inspection under high magnification verified that nano-EB did not stain healthy tissue. Nano-EB clearly aids in distinguishing @entity0 tissue from healthy tissue in an invasive @entity0 model, while injection of unencapsulated EB results in false identification of healthy tissue as @entity0 due to diffusion of dye from the @entity0 into healthy tissue.

title: Evans blue nanocarriers visually demarcate margins of invasive XXXX .

answer: @entity1


abstract: Dengue is the most common @entity1 of @entity0 and is a public health burden in more than 100 countries. @entity5 mosquitoes stably infected with strains of the intracellular bacterium Wolbachia are resistant to @entity2 and are being tested in field trials. To mimic field conditions, we experimentally assessed the vector competence of A. aegypti carrying the Wolbachia strains wMel and wMelPop after challenge with viremic blood from dengue @entity0 . We found that wMelPop conferred strong resistance to DENV @entity1 of mosquito abdomen tissue and largely prevented disseminated @entity1 . wMel conferred less resistance to @entity1 of mosquito abdomen tissue, but it did reduce the prevalence of mosquitoes with infectious saliva. A mathematical model of DENV transmission incorporating the dynamics of @entity4 in @entity0 and mosquitoes was fitted to the data collected. Model predictions suggested that wMel would reduce the basic reproduction number, R0, of DENV transmission by 66 to 75%. Our results suggest that establishment of wMelPop-infected A. aegypti at a high frequency in a @entity3 would result in the complete abatement of DENV transmission. Establishment of wMel-infected A. aegypti is also predicted to have a substantial effect on transmission that would be sufficient to eliminate dengue in low or moderate transmission settings but may be insufficient to achieve complete control in settings where R0 is high. These findings develop a framework for selecting Wolbachia strains for field releases and for calculating their likely impact.

title: Modeling the impact on virus transmission of Wolbachia-mediated blocking of @entity2 of XXXX .

answer: @entity5